Form PTC	1//0	U.S. Department of Commerce			ATTY. DOCKET NO. PRED. SERIAL NO.			heet 1 c	of <u>1</u> .
POIIT PTO-1444		Patent and Trademark Office					10/346,947 10/80059		
IN	FORM	ATION DISCLOS	URE STATEN	MENT	APPLICANT				
		BY APPLICA	•		Buckingham et al.				
DI ALLECAM					PRED. FILING DATE		PRED. GROUP		
	(U	se several sheets if necessary)			17 January 2003		1614		
				S. PATENT	DOCUMENTS				
Examiner		Document	Date		Name	Class	Subclass	Filing Date	
Initial	<del>  </del>	Number	1/00/00	ļ				If Appre	opriate
<u> </u>	AA	4,895,862	1/23/90	Alessi et		514	360		
- Ne	AB	5,068,342	11/26/91	Zask et al		548	183		
		1		EIGN PATE	NT DOCUMENTS				
		Document Number	Date		Country	Class	Subclass	Transl Yes	ation No
16	AC	EP 0 749 751	12/1996	EPO					
	AD	WO 93/03724	03/1993	PCT					
$\bot$	AE	WO 98/36755	8/1998	PCT					
)	AF	EP 0 861 666	09/1998	EPO					
1le	AG	WO 95/21608	08/1995	PCT					
		OTHER DOC	CUMENTS (In	cluding Aut	hor, Title, Date, Pertiner	nt Pages, El	c.)		
V.	AH	Donnelly et al., '	Drugs and	Insulin Res	sistance: Clinical Me	thods of E	valuation a	nd New	
W.		Pharmacological Approaches to Metabolism", Br. J. Clin Pharm., 37: 311-320 (1994).							
ſ	ΑI	Jackson et al., "Mechanism of Metformin Action in Non-Insulin-Dependent Diabetes",							
		Diabetes, <u>36</u> : 63	<b>2-640 (198</b> °	7)		_			
	AJ		ulin-Dependent Dial	oetes Mell	itus", The L	ancet, 3	43:		
	<u> </u>	95-100 (1994).							
	AK								
	AL Scheen et al., "Oral Antidiabetic Agents, A Guide to Selection". Dis. Manageme							nt, 55(2	):
		225-236 (XP002080821).							
	AM	A.J. Scheen, "Drug Treatment of Non-Insulin-Dependent Diabetes Mellitus in the 1990s.							
		Achievements and Future Developments". Drugs, 54(3): 355-368 (1997).							
	AN	Iwamoto et al., "Effect of Combination Therapy of Troglitazone and Sulphonylureas in							
		Patients with Type 2 Diabetes Who Were Poorly Controlled by Sulphonylurea Therapy							
		Alone". Diabetic Med., 13(4): 365-370 (1996).							
	AO	K. Doi, "New Oral Hypoglycemic Agents and Hypoglycemic Agents Under Developmen J. Japan Diabetes Sci., 3(S1): 962-973 (1990).							ıt".
	AP	N. Hotta, "How to Select and Use Oral Hypoglycemic Agents". Chronic Dis., 6(1): 1-9							
	711	(1995).							
	AQ	H. Lebovitz, "Stepwise and Combination Drug Therapy for the Treatment of NIDDM".							
		Diabetes Care, <u>17(12)</u> : 1542-1544 (1994).							
1	AR	Lehmann et al., "	'An Antidia	betic Thiaz	colidinedione is a High	h Affinity	Ligand for	Peroxi	some

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copyof this form with next communication to applicant.

n: \kls\cases\p31855c3\pto 1449 form.doc

Diabetes Care, 15(8): 1075-1078 (1992)

Proliferator-Activated Receptor γ (PPARγ)". J. Biol. Chem., 270: 12953-12956 (1995).

Hofmann et al., "New Oral Thiazolidinedione Antidiabetic Agents Act as Insulin Sensitizers",

DATE CONSIDERED

16

EXAMINER